News from cytrx corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 02, 2017, 09:00 ET CytRx Corporation Highlights Recent Progress at Freiburg, Germany, Laboratory and Provides Update for Oncology Pipeline

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted recent progress...

Oct 31, 2017, 09:00 ET CytRx Corporation Announces Reverse Stock Split

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the previously...

Oct 27, 2017, 14:15 ET CytRx Corporation Announces Results from Special Meeting of Stockholders

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the results of the...

Oct 16, 2017, 18:23 ET CytRx Corporation Announces Outcome of Nasdaq Hearing

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Nasdaq has...

Oct 12, 2017, 09:00 ET CytRx Corporation Highlights Inclusion of Aldoxorubicin in Pending Upcoming Clinical Trial Submissions Planned By Licensee NantCell, Inc.

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin ...

Oct 04, 2017, 09:00 ET Institutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote "FOR" the Proposed Reverse Stock Split

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Institutional...

Oct 02, 2017, 09:00 ET CytRx Corporation Provides Business Update and Highlights Future Plans

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today provided a business update and ...

Sep 21, 2017, 09:00 ET Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the Proposed Reverse Stock Split

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Glass Lewis &...

Sep 13, 2017, 09:00 ET CytRx Corporation Announces Amendment to Definitive Proxy Statement for Upcoming Special Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that based on...

Aug 30, 2017, 09:00 ET CytRx Corporation Files Definitive Proxy Statement for Upcoming Special Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has filed a...

Aug 24, 2017, 09:00 ET CytRx Corporation Announces Receipt of NASDAQ Listing Determination

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that, as...

Aug 21, 2017, 09:00 ET CytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting

CytRx Corporation (NASDAQ: CYTR) ("CytRx or "the Company"), a biopharmaceutical research and development company specializing in oncology, announced...

Aug 03, 2017, 09:00 ET CytRx Reports Second Quarter 2017 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...

Jul 28, 2017, 09:00 ET CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered...

Jun 13, 2017, 09:00 ET CytRx Announces Reshaping of Clinical and Regulatory Executive Team

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Shanta Chawla,...

Jun 08, 2017, 09:00 ET CytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR) a biopharmaceutical research and development company specializing in oncology, today announced an update on the...

May 17, 2017, 17:04 ET CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of...

May 10, 2017, 09:00 ET CytRx Reports First Quarter 2017 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...

Apr 28, 2017, 07:51 ET CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has priced a ...

Apr 27, 2017, 17:55 ET CytRx Corporation Announces Proposed Public Offering of Common Stock

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology today announced a proposed public...

Apr 21, 2017, 09:00 ET CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that an abstract...

Apr 19, 2017, 07:00 ET CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR) today announced the U.S. Food and Drug Administration (FDA) has reached an agreement with CytRx on preparations for...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE